Natera Announces Collaboration with Diakonos Oncology for Signatera™ in Refractory Melanoma
Natera announced a collaboration with Diakonos Oncology to use its Signatera test in a Phase I/II trial for refractory melanoma. Signatera will longitudinally assess molecular response via ctDNA analysis for patients receiving DOC1021, a personalized dendritic cell therapy with FDA Fast Track designation.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.